DexCom director granted 5,575 RSUs

Malady Kyle reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Malady Kyle reported acquisition or exercise transactions in this Form 4 filing.

DexCom Inc. director Kyle Malady received an equity award in the form of restricted stock units. The Form 4 reports a grant of 5,575 shares of Common Stock at no cash cost as a compensation-related award, bringing his direct holdings to 28,242 shares.

The award is structured as RSUs, each representing a contingent right to receive one DexCom share upon settlement. According to the terms, 100% of the RSU award will vest on the earlier of one year after the May 28, 2026 grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders.

Insider Trade Summary

Grant/Award: 5,575 shares

Grant/Award 1 txn

Insider Malady Kyle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,575	$0.00	$0.00

Holdings After Transaction: Common Stock — 28,242 shares (Direct)

Footnotes (1)

1. F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Key Figures

RSU grant size: 5,575 shares Post-grant holdings: 28,242 shares Grant price: $0.0000 per share +1 more

4 metrics

RSU grant size 5,575 shares Restricted stock units granted on May 28, 2026

Post-grant holdings 28,242 shares Common Stock directly held after the transaction

Grant price $0.0000 per share Compensation-related RSU award with no cash cost

Vesting schedule 100% cliff vest Earlier of one year from May 28, 2026 or 2027 Annual Meeting

Key Terms

restricted stock unit, RSU Award, Annual Meeting of Stockholders, Form 4

4 terms

restricted stock unit financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU Award financial

"The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier"

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DexCom (DXCM) report for Kyle Malady?

DexCom reported that director Kyle Malady received a grant of 5,575 restricted stock units. These RSUs are a compensation-related equity award, not an open-market purchase, and each RSU represents the right to receive one share of DexCom Common Stock upon settlement.

How many DexCom (DXCM) shares does Kyle Malady hold after this RSU grant?

After the grant of 5,575 restricted stock units, Kyle Malady is reported as directly holding 28,242 DexCom Common Stock shares. This figure reflects his position following the award and provides context for the size of the new grant relative to his existing holdings.

When do Kyle Malady’s DexCom (DXCM) RSUs vest?

The RSU award vests in full on the earlier of one year after the May 28, 2026 grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Vesting determines when the RSUs convert into actual DexCom Common Stock shares.

What does each DexCom (DXCM) restricted stock unit represent in this Form 4?

Each restricted stock unit represents a contingent right to receive one share of DexCom Common Stock. The units convert into shares upon settlement, after vesting conditions are satisfied, making RSUs a common form of equity compensation for directors and executives.

Was Kyle Malady’s DexCom (DXCM) RSU transaction a market buy or sell?

The filing classifies the transaction under code A as a grant, award, or other acquisition. This means the 5,575 RSUs were granted as compensation, with no per-share purchase price, rather than being bought or sold in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malady Kyle

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		5,575(1)	A	$0	28,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kyle Malady	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)